Funnel plots of all SNPs from (A) the conservative and (B) the expanded instrument set. SBP associations have been corrected by effect allele frequency as described by Bowden et al. previously.1 Red vertical line denotes combined GRS effect estimate from all SNPs.
Supplementary Figure 2.
Egger regression plots for the conservative and expanded genetic instruments. The slope of the regression line is the egger regression estimate for the effect of SBP on T2D risk (in log odds per mmHg). The y-intercept of the regression an estimate of the level and direction of bias present in the typical GRS or inverse-variance weighted estimate due to pleiotropy. A negative y-intercept in this case indicates that any bias present in this analysis will result in underestimation, rather than overestimation, of the causal effect size. 
Supplementary

Supplementary Figure 4.
Simulation analysis for sample ascertainment and analysis conditions from SBP genome-wide association studies. Results from n=1000 simulated GWAS of 150,000 individuals after adjusting for BMI, excluding diabetes cases, or both, under a model in which both BMI and SBP effect type 2 diabetes risk. (A) SBP association estimates for a representative SNP in our conservative instrument (rs6015450). The red horizontal line denotes the true effect size. (B) Mean error in effect estimates over n=13 SNPs used in conservative instrument.
Supplementary Figure 5.
Simulation results from n=1000 simulated GWAS generated as in Supplementary figure 4, but under a model in which only BMI effects T2D risk and SBP does not. (A) SBP association estimates for a representative SNP in our conservative instrument (rs6015450). The red horizontal line denotes the true effect size. (B) Mean error in effect estimates over n=13 SNPs used in conservative instrument. Figure 6 . Positive control experiment example of confounding due to Collider bias for BMI, using a representative SNP exclusively associated with SBP. Data shown are effect estimates (in standard deviations of BMI) from n=1000 simulated datasets of 150,000 individuals, based on a model in which both SBP and BMI have an effect on T2D risk. 
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Analyzing Egger Regression performance through simulation
Since the use of Egger Regression for Mendelian Randomization studies is a relatively novel technique 1 , we sought to better understand the behavior of this analytical tool through simulation. Using our conservative instrument as a baseline, simulated n=10,000 datasets for analysis by adding noise and bias to the T2D association of each SNP:
Where α is the true effect of SBP on T2D risk (set in these simulations at 0.02 log-odds increase per mmHg), J   is the T2D association estimate for the j th SNP generated for a given simulation, J   is the actual estimated SBP association, and J S  is the true standard error in T2D association for that SNP. By adjusting the upper and lower limits of the uniform distribution for the added bias, we were able to generate datasets affected by different levels and directions of pleotropic bias. The parameters for bias added are listed in Supplementary Table 5 .
From each these simulated datasets, we ran Egger regression analyses and estimated the power to detect bias. The complete R code (v3.3.0) used to simulate and analyze these datasets is available at https://github.com/raikens1/T2D_MR/. Using this set-up, we found that Egger regression power to detect negative bias is limited (Supplementary Table 6 ). Egger Regression effect estimates have a higher variance when bias is at play (6 x 10 ). However, the effect estimates from this test are still correct on average (Supplementary Figure 3 , two-tailed t-test for significant error under negative bias: p = 0.45).
In Silico Test for bias due to adjustment in the primary scan
In order to understand whether adjustment for adiposity in the primary scan resulted in bias in our GRS, we simulated GWAS under two different causal models:
A. Both BMI and SBP affect T2D risk B. BMI, but not SBP, affects T2D risk Under each causal model, we used the MR_predictor simulation engine described previously 2 to generate n=1000 sets of genotype and phenotype from 150,000 individuals. To construct our simulations, association of SBP with BMI 3 , and BMI-associated T2D risk 4 were drawn from the literature, and the T2D prevalence was tuned to give a realistic case/control ratio in simulation (targeting a 9.8% diabetes prevalence, in agreement with estimates by Cowie et al. 5 ).We then used the Plink analysis toolset (v1.07) 6, 7 to generate linear SBP association estimates for each of the 13 SNPs in our conservative instrument set over n=1000 simulations. As a summary statistic, we observed the distribution of the mean error over all SNPs, as:
where that γ j and γ ij -hat respectively represent the actual SBP association of the j th SNP and the estimate for that association generated from the i th simulation (where the association for a given SNP is always relative to the blood-pressure-increasing allele). Mean errors were tested for significance using a twosided t-test in R (v3.3.0). The code used to run plink and MR_predictor and the relevant MR_predictor input files are available at https://github.com/raikens1/T2D_MR/, and the MR_predictor simulation toolset and documentation are additionally available online (http://coruscant.itmat.upenn.edu/mr_predictor/).
We found in both scenarios that, even when certain corrections in the primary scan did result in statistically significant bias, the magnitude of this change was sufficiently small compared to our estimated SBP associations that it could not be expected to have any notable effect on our final result (Supplementary Figures 4 and 5) .
As an additional check, we sought to demonstrate that our simulation framework was sufficient to detect strong collider bias if it did indeed arise (collider bias has been illustrated previously 8 ). Since high BMI is known to cause high blood pressure [9] [10] [11] , adjusting for SBP in a linear association analysis will cause SBP-related SNPs to falsely associate with BMI. We used the PLINK toolset to perform these association analyses for n=1000 simulated datasets under the model that both SBP and BMI increase type two diabetes risk. When SBP was used as a covariate in these analyses, we found that simulations tended to report a false BMI association for SNPs related exclusively to SBP (Supplementary Figure  6) .
In Silico Test for bias due to pro-diabetic antihypertensive use in GWAS cohorts
Since evidence suggests that various antihypertensive medications (namely beta-blockers and thiazide diuretics) are linked to increased type 2 diabetes risk, we considered the possibility that the putative link between SBP and type 2 diabetes risk can be explained by the use of diabetogenic antihypertensive use by the subjects of our GWAS cohorts. If hypertensive subjects used an antihypertensive medication that increased diabetes risk, we would expect our risk score to be positively biased. This is because we expect, based on genotype, a log-additive increase in drug use on a liability scale (with respect to blood pressure). Put another way: each genetic variant increases the chance of crossing the hypertension liability threshold by a small amount. Each variant thus increases drug use amount proportional to the SBP effect. This applies to each SNP: weaker-effect SBP SNPs have lower chance for antihypertensive use, while stronger SBP SNPs will contribute a greater chance. Individuals will carry a random collection of these variants. However, the impact of drug use on type 2 diabetes risk is the same (the magnitude of the effect does not change by genotype). This is analogous to systemic, positive bias from unmeasured confounding, which can be measured and subsequently accounted for by Egger Regression.
We performed a simulation experiment to verify this intuition. We generated 33K cases and 33K controls, the equivalently powered effective symmetric sample size of our T2D study. Among simulated subjects, we assumed 60% of T2D cases were hypertensive (> 140 mmHg SBP), 30% of controls as hypertensive. These rough estimates were obtained from recent literature 12, 13 . Then, we varied (from 0-100%) the percentage of hypertensive subjects that take a drug that increases T2D risk, and assumed that this drug use increases T2D by 1.4-fold (according to a literature estimate for beta blockers 14 ). This boils down to T2D subjects having a higher prevalence of an exposure (i.e., drug use) that increases the baseline risk for a subset of participants (i.e. hypertension).
Simulations demonstrate a positive bias that grows in magnitude as the percent of pro-diabetic antihypertensive drug use among subjects who are hypertensive increases (see Supplementary Table 7 , below). This effect also resulted in a corresponding reduction in the casual effect from the Egger Regression analysis, as one would expect in the presence of positive, directional confounding (Supplementary Table 7 ). This effect also does slightly increase the casual effect estimate from the GRS method (0.540 for no drug use to 0.556 for 100% drug use, Supplementary Table 7) . Based on this analysis, we did not observe significant evidence of bias for either of our risk scores. Moreover, the direction of that term trended toward negative, rather than positive, contrary to what would be expected from this drug-confounding effect. While assumptions made here are unlikely to perfectly match the specifics of the contributing T2D cohort(s) to our study, the results support our intuition above: (i) that the direction of this type of bias should be positive, (ii) that Egger regression can identify (and adjust) for this effects, at least under this specific model, and (iii) that in the real data, we observed a trend in the opposite direction of this putative effect: negative rather than positive bias.
